FOLH1 and prostate cancer: The structure comprises the main fragments: radionuclide (Lu-177)—a source of β− radiation; targeting ligand (vipivotide)—a PSMA-binding peptide (Lys-Urea-Glu) that specifically targets prostate cancer cells, as PSMA is significantly overexpressed on their surface; chelator (tetraxetan)—a chemical moiety that securely binds the radionuclide to the targeting ligand; hydrophobic linker, composed of 2-naphthyl-L-Ala and cyclohexyl groups, it connects the targeting ligand to the chelator, influencing the compound’s pharmacological properties (Figure 7).